Since the discovery that IgE antibodies mediate allergy, decades of research have unraveled complex mechanisms associated with conventional immunotherapy and the vital protagonists that shape ‘immune tolerance’ to allergens. Debate exists on what should constitute the dominant effector mechanism in driving rational drug designs for next-generation immunotherapies. As vaccine technology continues to advance, the development of novel vaccines in this area of continued medical need might stand on a threshold of breakthrough inspired by experiments by Dunbar on the passive vaccination of allergic animals more than 100 years ago. In this opinion article, we discuss both novel insights into IgG antibodies as the principle effector modality induced by specific immunotherapy and advances in antigen-carrier design that may catapult allergy treatment into our modern world.

自从发现IgE抗体介导变态反应以来，数十年的研究揭示了与常规免疫疗法和形成对变应原“免疫耐受”的重要角色有关的复杂机制。关于在驱动下一代免疫疗法的合理药物设计中应构成主导效应机制的争论尚存在。随着疫苗技术的不断发展，在不断医疗需求这一领域中开发新型疫苗可能会站在突破门槛上，这一突破源于100多年前Dunbar对过敏性动物进行被动接种的实验所激发。在这篇评论文章中，